Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with <sup>177</sup>Lu-PSMA radioligand therapy.

von Eyben, Finn Edler; Kulkarni, Harshad R; Baum, Richard P

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with ¹⁷⁷Lu-PSMA radioligand therapy.

von Eyben, Finn Edler; Kulkarni, Harshad R; Baum, Richard P.

Afiliação

von Eyben FE; Center of Tobacco Control Research, Odense, Denmark.
Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Baum RP; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.

Theranostics ; 10(11): 4900-4902, 2020.

Article em En | MEDLINE | ID: mdl-32308757

Assuntos

Neoplasias de Próstata Resistentes à Castração; Dipeptídeos; Compostos Heterocíclicos com 1 Anel; Humanos; Masculino

Palavras-chave

177Lutetium [177Lu]-PSMA radioligand therapy; overall survival; prostate specific membrane antigen; prostatic neoplasms; restaging

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Theranostics Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google